OVID (Ovid Therapeutics Inc. Common Stock) Stock Analysis - News
Ovid Therapeutics Inc. Common Stock (OVID) is a publicly traded Healthcare sector company. As of May 21, 2026, OVID trades at $2.42 with a market cap of $449.80M and a P/E ratio of 0.00. OVID moved -0.42% today. Year to date, OVID is +43.98%; over the trailing twelve months it is +724.71%. Its 52-week range spans $0.24 to $3.11. Analyst consensus is strong buy with an average price target of $5.33. Rallies surfaces OVID's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in OVID news today?
Ovid Therapeutics Doses KCC2 Activator, Raises $60M PIPE, $53.9M Warrants, Ends Q1 with $165.6M: Ovid Therapeutics initiated Phase 1 dosing of oral KCC2 activator OV4071 in May and reported OV329 cohorts showed favorable safety and PK supporting planned Phase 2. The company raised $60 million in March PIPE financing, generated $53.9 million from warrant exercises and ended Q1 with $165.6 million in cash equivalents.
Ovid Therapeutics Doses KCC2 Activator, Raises $60M PIPE, $53.9M Warrants, Ends Q1 with $165.6M: Ovid Therapeutics initiated Phase 1 dosing of oral KCC2 activator OV4071 in May and reported OV329 cohorts showed favorable safety and PK supporting planned Phase 2. The company raised $60 million in March PIPE financing, generated $53.9 million from warrant exercises and ended Q1 with $165.6 million in cash equivalents.
Does Rallies summarize OVID news?
Yes. Rallies summarizes OVID news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is OVID research on Rallies investment advice?
No. Rallies provides research, data, and educational context for OVID. It does not provide personalized investment advice.
